Navigation Links
FDA Clears New Applicators for Endometrial Cancer Treatment With Xoft's Axxent(R) Electronic Brachytherapy System
Date:5/21/2008

Second Treatment Indication on Heels of Multi-Use Clearance for Axxent(R) System Strengthens the Creation of a New Platform in Radiation Therapy

SUNNYVALE, Calif., May 21 /PRNewswire/ -- Xoft, Inc., today announced that it has received clearance from the U.S. Food & Drug Administration (FDA) for applicators to be used with the Axxent(R) Electronic Brachytherapy System for the treatment of endometrial cancer. Previously cleared for accelerated treatment of early stage breast cancer, the Axxent System, a proprietary technology platform designed to deliver localized, non-radioactive, isotope-free radiation treatment in minimally-shielded clinical settings, also recently received expanded FDA Clearance for use in the treatment of other cancers or conditions where radiation therapy is indicated.

Endometrial cancer, the most prevalent gynecologic cancer in the United States, is also the fourth most common invasive cancer and represents six percent of all cancer in women. It is a disease where malignant cells form in the tissues of the lining of the uterus, or endometrium. According to the National Cancer Institute, more than 40,000 cases will be diagnosed in 2008 and will result in nearly 7,500 deaths.

While treatment options vary, endometrial cancer is generally treated with surgery, frequently a hysterectomy to remove the uterus, and radiation therapy. Shown to reduce local recurrence, radiation therapy also improves survival in some cases, according to a retrospective study involving more than 21,000 patients published in the Journal of the American Medical Association. The use of brachytherapy for endometrial cancer is well established among radiation oncologists and the trend has been increasing as clinical experience shows benefits. Nearly two-thirds of cases, approximately 25,000, are eligible for treatment with internal brachytherapy exclusively or in combination with external beam therapy. The American Brachytherapy Society (ABS) has e
'/>"/>

SOURCE Xoft, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
2. Federal Trade Commission Clears Kyphons Acquisition of Non-Vertebroplasty Spine-Related Assets of Disc-O-Tech
3. FDA Clears OmniWave(TM) Endovascular System for Clot Removal in Peripheral Blood Vessels
4. FDA Clears Biospace meds Revolutionary Low Dose Xray Imager
5. New filter clears up fiber optic communications
6. FDA Clears Expanded Use of Xofts Axxent(R) Electronic Brachytherapy System for all Radiation Therapy Indications
7. Device That Clears Debris From Artery Aids Blood Flow in PCI
8. FDA Clears First Medical Product Made From Yulex(R) Natural Rubber
9. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
10. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
11. Johns Hopkins to add Elekta Synergy S(R) to Cancer Treatment Lineup
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... (PRWEB) December 23, 2014 Pipette.com announces ... their Twitter followers can submit their #HolidayInTheLab pictures for ... their lab mates. , For those struggling to think ... the Pipette.com Holiday in the Lab Contest provides the ... Twitter followers to send pictures of their chemistree, ...
(Date:12/24/2014)... , Dec. 23, 2014 Sigma-Aldrich ... that the waiting period under the Hart-Scott-Rodino Antitrust ... acquisition expired on December 22, 2014, thereby completing ... requirement for the acquisition of the Company by ... antitrust clearance satisfies another condition to closing the ...
(Date:12/22/2014)... 22, 2014   Synthetic Biologics, Inc. ... pathogen-specific therapies for serious infections and diseases, ... today announced positive topline safety and tolerability ... of SYN-004, the Company,s investigational oral beta-lactamase ... difficile (C. difficile) infection, antibiotic-associated diarrhea ...
(Date:12/22/2014)... 22, 2014  ( www.competitivehealth.com ) — Competitive Health ... bill review and advocacy service, has signed an agreement ... Savings discount health services marketplace. 63% of ... than they expected to pay. As part of an ... WellCard Savings is pleased to offer medical bill review ...
Breaking Biology Technology:Major Pipette Distributor Pipette.com Announces their Holiday in the Lab Contest 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2
... 3 Inverness Medical Innovations, Inc. (NYSE: IMA ), ... health at home through the merger of rapid diagnostics and health ... Series B Convertible Perpetual Preferred Stock ( IMA-PB). The dividend will ... per share equal to the quotient of (a) $3.00 divided by ...
... , ... that a new market research report is available in ... Perspective , http://www.reportlinker.com/p0164232/Neurostimulation---A-Global-Market-Perspective.html , The ... of aging population, and the resultant rise in age-related ...
... , TUSTIN, Calif., Dec. ... reported completion of patient enrollment in a dose confirmation and ... (GBM), the deadliest form of brain cancer. Cotara is ... as a potential new treatment for GBM. Cotara specifically ...
Cached Biology Technology:Reportlinker Adds Neurostimulation - A Global Market Perspective 2Reportlinker Adds Neurostimulation - A Global Market Perspective 3Reportlinker Adds Neurostimulation - A Global Market Perspective 4Reportlinker Adds Neurostimulation - A Global Market Perspective 5Reportlinker Adds Neurostimulation - A Global Market Perspective 6Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 2Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 3Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 4Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 5
(Date:12/10/2014)... Dec. 8, 2014 You,ve been here before: you ... can,t remember your password, site key or the answer to ... first grade teacher? Today, Hoyos Labs ... app that will finally put an end to the frustration ... TM . 1U leverages a user,s smartphone to acquire ...
(Date:12/10/2014)... Dec. 08, 2014 Research and Markets ... of the "Biometrics Market in Japan 2014-2018" ... http://photos.prnewswire.com/prnh/20130307/600769 The integration ... as rural banking and upgradation of the driver,s ... in the market. Besides the aforementioned projects, biometrics ...
(Date:12/4/2014)... , Dec. 3, 2014  Crossmatch™, a ... announced that its DigitalPersona ® Pro Enterprise ... have been deployed throughout First Bank branch locations ... South Carolina and Virginia. First Bank, ... Southern Pines, North Carolina , selected ...
Breaking Biology News(10 mins):The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3
... evidence that most, if not all cases of chronic ... originally proposed by investigators at the Mayo Clinic. ... ongoing pivotal Phase 3 clinical trial for its lead ... amphotericin B 0.01% suspension. In order to be ...
... the Georgia Institute of Technology have developed a new ... of being used in a range of environments including ... the technique, known as thermochemical nanolithography, as a proof ... a variety of nanopatterned structures, including nanocircuits, at a ...
... 10 September 2007 Elsevier, a leading publisher ... announced the availability of more than 4,000 eBooks ... titles published from 1995 to the present. These ... areas, as well as books from renowned imprints ...
Cached Biology News:SinuNase Phase 3 show almost 100 percent of chronic sinusitis cases are from fungal-induced inflamma 2Drawing nanoscale features the fast and easy way 2Drawing nanoscale features the fast and easy way 34,000 e-Books now available on ScienceDirect 2